Navigation Links
Alchemia Reports Preliminary Positive Efficacy Data From HyCAMP,Phase II Trial

ure studies with the FDA. We are hopeful that these results will enable us to move forward to a pivotal phase III study earlier than originally anticipated."

These results are important not only for the development and approval path for HyCAMP(TM) itself but they provide validation of the technology platform. The HyACT(TM) platform is an extremely flexible formulation technology as it can be used with virtually any intravenously administered anti-cancer treatment. We have successfully completed Phase I clinical studies on HyACT(TM) formulations of two other chemotherapy drugs, doxorubicin and 5- flurouracil. Encouraging preclinical data has also been obtained on a number of other cytotoxics. More recently, we have demonstrated in preclinical studies that HyACT(TM) can also be used to significantly enhance the efficacy of newer targeted antibody therapies such as Avastin(TM) and Erbitux(TM) In the case of generic drugs or drugs close to patent expiry, the HyACT(TM) formulation may provide a means for companies to differentiate their products from other competitors in the market place, and thereby build product value.

HyCAMP(TM) and the proprietary formulation technology, HyACT(TM), were obtained following the successful acquisition of Melbourne based oncology company Meditech Research Limited in 2006. "The Phase II clinical results provide proof of concept for the HyACT(TM) platform. We expect this technology to build substantial value for shareholders, not only with HyCAMP(TM), but with other oncology drugs as well" Dr Ramsdale said.

Before HyCAMP(TM) can be marketed in the US, the drug needs to successfully complete a Phase III study, and receive marketing approval from the US FDA.

Alchemia wishes to acknowledge the commitment and thank the patients who volunteered to participate in this trial, and to acknowledge and thank the investigators, study research personnel and nursing staff at the 10 clinical sites across Australia who looked a
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:3/3/2015)... , March 3, 2015 /CNW/ - ... seized a health product being injected at Art Nails Ltd., ... which appeared to be unauthorized as it contained no labelling. All ... be authorized by Health Canada and must have approved labelling. ... that had been administered to consumers. Potential risks associated with injecting ...
(Date:3/3/2015)... , March 3, 2015 ... 356 and 240 patients respectively Publications in ... Journal of Clinical Gastroenterology highlight diagnostic value of ... China and across ... Kea Technologies (Euronext: MKEA, FR0010609263), inventor of Cellvizio®, the ...
(Date:3/3/2015)... Research and Markets ( http://www.researchandmarkets.com/research/x5lz9r/global_poc ) ... Diagnostics Market 2015-2019" report to their offering. ... Diagnostics market to grow at a CAGR of 8.47 ... diagnostics are IVD devices and tools used for diagnosing ... use of these devices helps in the rapid diagnosis ...
Breaking Medicine Technology:Advisory - Health product seized from Art Nails in Vancouver 2Two New Publications From Leading Team in China Present Data From Large Clinical Trials Highlighting Advantages of Cellvizio in Diagnosis of Gastric and Esophageal Cancers 2Two New Publications From Leading Team in China Present Data From Large Clinical Trials Highlighting Advantages of Cellvizio in Diagnosis of Gastric and Esophageal Cancers 3Two New Publications From Leading Team in China Present Data From Large Clinical Trials Highlighting Advantages of Cellvizio in Diagnosis of Gastric and Esophageal Cancers 4Global POC Diagnostics Market 2015-2019 with Abbott Labs, Alere, Bayer Healthcare, Danaher, F. Hoffmann-La Roche & Johnson & Johnson Dominating 2
(Date:3/4/2015)... Information Innovators Inc . (Triple-i) is honored ... the company as Chief Technology Officer. Mr. Dvorak will ... company, including customer-centric strategies and initiatives, and promoting continuous ... as a technology executive and visionary. Prior to joining ... including oversight of enterprise data management, analytic software development, ...
(Date:3/4/2015)... 04, 2015 In a small ceremony with ... on their new facility in New Port Richey on February ... new facility will allow the Florida drug detox facility ... drug abuse epidemic through treatment and education. “Due to our ... in the United States, we made the decision that expanding ...
(Date:3/4/2015)... 2015 i2i Systems Population Health ... Chase Brexton Health Care, a 35-year-old Maryland-based community ... Brexton provides comprehensive primary care, behavioral health and ... seven clinics in the greater Baltimore area of ... records, the organization has always focused on providing ...
(Date:3/4/2015)... March 04, 2015 Dietary supplement company ... the world’s first biocompatible copper chelate, at Natural Products ... guests the chance to gain insight into their wellness ... the Cunermuspir complex can support their individual nutritional needs, ... which is the core ingredient of the MitoSynergy product ...
(Date:3/4/2015)... 2015 The report “Vasculitis – Pipeline ... development for Vasculitis. Vasculitis is a disease that features ... vasculitis diseases is not known. Vasculitis can affect any ... symptoms. Symptoms can include fever, weight loss, tiredness, aches, ... in a limb. Vasculitis is treatable, but it is ...
Breaking Medicine News(10 mins):Health News:Information Innovators Inc. Announces Mr. John Dvorak as the New Chief Technology Officer 2Health News:Information Innovators Inc. Announces Mr. John Dvorak as the New Chief Technology Officer 3Health News:Novus Medical Detox Hosts Ribbon Cutting Ceremony at Pasco County Facility 2Health News:Novus Medical Detox Hosts Ribbon Cutting Ceremony at Pasco County Facility 3Health News:Chase Brexton Selects i2i Systems Population Health Management Solutions to Demonstrate HEDIS Quality Outcomes to Maryland’s Health Plans 2Health News:Chase Brexton Selects i2i Systems Population Health Management Solutions to Demonstrate HEDIS Quality Outcomes to Maryland’s Health Plans 3Health News:MitoSynergy Invites Expo West Attendees to Sit Back, Relax and Take Time for Their Health 2Health News:Vasculitis Therapeutics Pipeline H1 2015 Review Report Available at RnRMarketResearch.com 2Health News:Vasculitis Therapeutics Pipeline H1 2015 Review Report Available at RnRMarketResearch.com 3Health News:Vasculitis Therapeutics Pipeline H1 2015 Review Report Available at RnRMarketResearch.com 4
... the MetLife Foundation Awards for Medical Research ... today, at a scientific briefing and luncheon that honors two ... Alzheimer,s and the substances in the brain that play an ... S. Wolfe , Ph.D., professor of neurology at Harvard ...
... 18 Natural Harmony,Foods, Inc., (Pink Sheets: NHYF) is ... has succeeded in moving on to the next round ... Natural Harmony Foods was,invited to enter this prestigious annual ... to consumers each year. , ...
... Shows Five Masimo Rad-57 Pulse CO-Oximeters(TM) Detected 83 Unsuspected ... UK Reported Annual CO PoisoningsIRVINE, Calif., Feb. 18 ... Pulse CO-Oximetry and Measure-Through Motion and Low-Perfusion pulse oximetry, ... UK House of Commons All Party Parliamentary Gas Safety ...
... MinuteClinic, the pioneer and largest provider of ... that it has become a participating provider in ... is the uniformed services health care program for ... service members and their families, members of the ...
... Pharmaceuticals, Inc. (Nasdaq: ARNA ) announced ... trial of an orally administered niacin receptor agonist drug ... its collaboration with Arena to treat atherosclerosis. Agonists of ... lipid profiles, including HDL, or the "good" cholesterol, similar ...
... - results from this trial supported entry into ... cancer program -,BELLEVILLE, ON, Feb. 18 /PRNewswire-FirstCall/ - ... technology-driven Canadian biopharmaceutical company, today announced that The ... the Phase II clinical trial results for the ...
Cached Medicine News:Health News:Two Scientists Honored with MetLife Foundation Awards for Medical Research in Alzheimer's Disease 2Health News:Two Scientists Honored with MetLife Foundation Awards for Medical Research in Alzheimer's Disease 3Health News:Two Scientists Honored with MetLife Foundation Awards for Medical Research in Alzheimer's Disease 4Health News:Two Scientists Honored with MetLife Foundation Awards for Medical Research in Alzheimer's Disease 5Health News:Two Scientists Honored with MetLife Foundation Awards for Medical Research in Alzheimer's Disease 6Health News:Natural Harmony Foods, Inc. Advances to the Next Round of America's Healthiest Food Awards 2Health News:Natural Harmony Foods, Inc. Advances to the Next Round of America's Healthiest Food Awards 3Health News:United Kingdom House of Commons Safety Group Recommends Carbon Monoxide Screening by Pulse CO-Oximetry(TM) to Reduce Misdiagnosis and Prevent Deaths 2Health News:United Kingdom House of Commons Safety Group Recommends Carbon Monoxide Screening by Pulse CO-Oximetry(TM) to Reduce Misdiagnosis and Prevent Deaths 3Health News:United Kingdom House of Commons Safety Group Recommends Carbon Monoxide Screening by Pulse CO-Oximetry(TM) to Reduce Misdiagnosis and Prevent Deaths 4Health News:United Kingdom House of Commons Safety Group Recommends Carbon Monoxide Screening by Pulse CO-Oximetry(TM) to Reduce Misdiagnosis and Prevent Deaths 5Health News:United Kingdom House of Commons Safety Group Recommends Carbon Monoxide Screening by Pulse CO-Oximetry(TM) to Reduce Misdiagnosis and Prevent Deaths 6Health News:MinuteClinic Becomes Participating Provider for Health Net Federal Services/TRICARE North, Insurer for Military Families 2Health News:MinuteClinic Becomes Participating Provider for Health Net Federal Services/TRICARE North, Insurer for Military Families 3Health News:Arena Pharmaceuticals Announces Initiation by Merck of Phase 2 Clinical Trial of Niacin Receptor Agonist 2Health News:Arena Pharmaceuticals Announces Initiation by Merck of Phase 2 Clinical Trial of Niacin Receptor Agonist 3Health News:Bioniche Phase II Bladder Cancer Trial Results Published in The Journal of Urology 2Health News:Bioniche Phase II Bladder Cancer Trial Results Published in The Journal of Urology 3Health News:Bioniche Phase II Bladder Cancer Trial Results Published in The Journal of Urology 4
Providing a perfect combination of capacity, speed and innovation, the Concept 400 delivers simple sophistication and new levels of comfort and convenience....
Lose the variability of anaerobic jars and step into the 21st century with the anaerobic workstation that provides the answer to the common problems associated with anaerobic microbiology....
... MARS Enduro is the ideal partner ... required before, during or directly after ... longitudinal adjustment and the filigreed construction, ... in examination, induction and operating theatre. ...
23" Top Slide with Full Table Functions for Every Procedure...
Medicine Products: